{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-222746","form_type":"8-K","ticker":"LRMR","cik":"0001374690","company_name":"Larimar Therapeutics, Inc.","filed_at":"2026-05-14T11:02:34+00:00","discovered_at":"2026-05-14T11:05:00.347530+00:00","generated_at":"2026-05-14T11:07:51.306255+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Larimar plans rolling BLA for nomlabofusp in June 2026; Q1 net loss $29.6M","bullets":["Net loss Q1 2026 $29.6M ($0.31/sh) vs Q1 2025 $29.3M ($0.46/sh). Cash $200.4M.","Intends to initiate rolling BLA seeking accelerated approval June 2026; CMC module H2 2026.","Topline open-label study data expected Q2 2026; Phase 3 first patient dose mid-2026.","Breakthrough Therapy Designation granted Feb 2026. Skin frataxin as surrogate endpoint supported by published data.","Feb 2026 $115M public offering extended cash runway into Q2 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-222746","json":"https://secwatch.observer/filing/0001193125-26-222746.json","markdown":"https://secwatch.observer/filing/0001193125-26-222746.md","text":"https://secwatch.observer/filing/0001193125-26-222746.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374690/000119312526222746/0001193125-26-222746-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374690/000119312526222746/lrmr-20260514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T11:07:51.306255+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}